TLR7 and COVID-19: The selective TLR7/8 inhibitor enpatoran was proposed as one of the drugs with promise for the treatment of COVID-19, but treatment with enpatoran in hospitalized patients with acute COVID-19 pneumonia did not cause significant positive clinical changes and, on average, increased the recovery time compared to patients receiving placebo [623].